The effects of pemafibrate in Japanese patients with type 2 diabetes receiving HMG-CoA reductase inhibitors.

CONCLUSION: The statin-pemafibrate combination therapy in type 2 diabetes patients with dyslipidemia improved lipid metabolism safely without increasing the risk of hepatic dysfunction and myopathy.
PMID: 32819242 [PubMed - as supplied by publisher]

Source: Endocrine, Metabolic and Immune Disorders Drug Targets - August 17, 2020 Category: Endocrinology Authors: Kusunoki M, Sakazaki T, Tsutsumi K, Miyata T, Oshida Y Tags: Endocr Metab Immune Disord Drug Targets Source Type: research